论文部分内容阅读
自本世纪至七十年代初,充血性心力衰竭(CHF)的治疗无明显进展。其方法不外乎是限制体力活动和钠盐的摄入以及使用洋地黄类药物和利尿剂。然而近年来,新的研究手段促进了对 CHF 病理,生理了解,因而相应地使 CHF 的治疗有了很大进展,血管扩张药,特别是具有相对特异性的血管扩张药以及具有正性肌力的非洋地黄糖苷拟交感胺等的问世,还有一些旧药新用,为 CHF 的治疗开辟了新的途径。氨联吡啶酮(Amrinone)这是一近新近合成的强心药,其分子式为〔5-氨基-3,4′-双吡啶-6(IH)-酮〕。该药具有明显的正性机力作用,经动物和临床使用证明,其正性肌力作用与Na~+、K~+—ATP 酶,cAMP (环状-磷酸
There has been no significant improvement in the treatment of congestive heart failure (CHF) from the early 2000s to the early 1970s. Its approach is nothing more than to limit physical activity and sodium intake and the use of digitalis and diuretics. However, in recent years, new research methods to promote the pathological and physiological understanding of CHF, which in turn has made great progress in the treatment of CHF, vasodilators, especially with relatively specific vasodilators and with positive inotropic The advent of non-digitalis glycosides such as sympathomimetics, as well as some new use of old drugs, opened up new avenues for the treatment of CHF. Amrinone This is a newly synthesized, cardiotonic drug of the formula [5-Amino-3,4’-bipyridin-6 (IH) -one]. The drug has obvious positive force, animal and clinical use proved that its positive inotropic effect with Na ~ +, K ~ + -ATPase, cAMP (cyclic - phosphate